2016_Head & Neck COURSE BOOK

Loco regional control and p16 ‐ St. I-II p16+ 90% St. III-IV p16+ 87%

St. III-IV p16- 62% St I II p16 57% . - -

DAHANCA 2000‐2013, curative intent RT, oropharynx patients with known p16 status (n=1163)